I worry about the same with cabotegravir prep.

Not because thrush is a critical OI but more as evidence that anti-cd4 and low cd4 in these patients does (or doesn’t) impact immune response

For sure, outcomes data is so hard to get critical mass to make conclusions, especially for more rare OIs. I do wonder if querying thrush diagnosis or treatment would be frequent enough to still see a signal here.

This is excellent and interesting! Any plans to look at OI outcomes?

Cant wait, the waxing poetical phase of innoculum effect has worn thin

Also helpful in these sub-analyses that aren’t p value approved to show all the data: do the comorbidities skew hard in these smaller groups with innoculum effect based on treatment received?

This one is a bit fuzzy to me. Why isn’t the comparison in efig3 more direct: cefazolin vs oxacillin for each innoculum effect instead of presence of abscence.

Looks like in figure 2 almost all cefazolin InE strains also had oxacillin InE (but not vice versa)?

#3 can be great, but key is to give the fellow the appropriate tools and system for finding quality research on a topic. Easy to get in the weeds as a trainee.

Seems like culture negative sepsis might be a wide net that includes a number of non-infectious etiologies that wouldn’t be antibiotic responsive and have poor prognosis. Were they “Pulmonary origin sepsis” or organ failure resulting in pulmonary syndrome. (Hepatopulmonary, cardiopulmonary).

“Oh, I always am cold”
-patients that think their struggle is finally being seen when I ask about chills…